Patents by Inventor Thomas Linnemann
Thomas Linnemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140170145Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: October 8, 2013Publication date: June 19, 2014Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Patent number: 8575312Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: GrantFiled: April 13, 2012Date of Patent: November 5, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20120258071Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Patent number: 8178109Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: GrantFiled: February 12, 2009Date of Patent: May 15, 2012Assignee: Five Prime Therapeutics, Inc.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20110003384Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: February 12, 2009Publication date: January 6, 2011Inventors: Dirk BEHRENS, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20100210829Abstract: Provided herein are novel polypeptides, polynucleotides and compositions containing such, and to methods useful in treating diseases, disorders, or conditions of the central nervous system (CNS) associated with demyelination. The novel polypeptides, polynucleotides stimulate oligodendrocyte precursor cell (OPC), and are capable of promoting myelination or remyelination in a subject.Type: ApplicationFiled: March 7, 2008Publication date: August 19, 2010Applicant: Five Prime Therapeutics, Inc.Inventors: Thomas Linnemann, Lorianne Masuoka, Srinivas Kothakoto, Stephen Doberstein
-
Publication number: 20080286834Abstract: The present invention provides leader sequences that are useful for the production of heterologous secretable polypeptides; heterologous secreted polypeptides; nucleic acid constructs that encode such leader sequences and heterologous secreted polynucleotides; vectors that contain such nucleic acid constructs; recombinant host cells that contain such nucleic acid constructs; vectors, polypeptides, and methods of making and using such secreted polypeptides with such heterologous leader sequences.Type: ApplicationFiled: January 27, 2006Publication date: November 20, 2008Inventors: Robert Forgan Halenbeck, Elizabeth Bosch, Thomas Linnemann, Ernestine Lee
-
Publication number: 20080242603Abstract: Disclosed are newly identified Interleukin 24 and APO2L splice variant molecules, their polypeptide sequences, and the polynucleotides encoding the polypeptide sequences. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells, and, for example, heterologous secretory leader sequences. Also disclosed are methods for using such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.Type: ApplicationFiled: February 18, 2005Publication date: October 2, 2008Inventors: Yan Wang, Amy L. Tsui Collins, Kevin Hestir, Ernestine Lee, Forgan Robert Halenbeck, Elizabeth Bosch, Thomas Linnemann, Lewis Thomas Williams
-
Publication number: 20070264277Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: July 21, 2005Publication date: November 15, 2007Inventors: Dirk Behrens, Elizabeth Bosch, Stephen Doberstein, Robert Halenbeck, Kevin Hestir, Min Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin Wong, Ge Wu, Aileen Zhou
-
Publication number: 20070160816Abstract: A method is described for producing a decorative laminate including: providing a decorative layer, applying a mixture of a thermohardening synthetic resin and hard particles to said layer, pressing the decorative layer and the mixture in a hot press at a press temperature in order to obtain a laminate, the mixture also containing a wax whose melting point is less than approximately 140° C. and/or by more than approximately 50° C. lower than the press temperature. A decorative laminate, a decorative laminate board and a method for producing a decorative prepreg sheet are also disclosed.Type: ApplicationFiled: November 26, 2004Publication date: July 12, 2007Applicant: Thomas C. LinnemannInventor: Thomas Linnemann
-
Patent number: 5107857Abstract: A disposable decontamination device, comprising a fordable frame expandable to define a rectangular shape sized to accommodate a patient, a fluid resistant fabric formed into a basin sized to enclose said frame when positioned a patient on a backboard in on said basin and a collection vessel and drain means for transferring fliud from said basin to said vessel.Type: GrantFiled: April 27, 1990Date of Patent: April 28, 1992Assignee: Radiation Management Consultants, Inc.Inventors: Thomas Linnemann, Kurt Linnemann
-
Patent number: 4960136Abstract: A disposable decontamination device, comprising a foldable frame expandable to define a rectangular shape sized to accommodate a patient, a fluid resistant fabric formed into a basin sized to enclose said frame when positioning a patient on a backboard in one said basin and a collection vessel and drain means for transferring fluid from said basin to said vessel.Type: GrantFiled: April 10, 1989Date of Patent: October 2, 1990Assignee: Radiation Management Consultants, Inc.Inventors: Thomas Linnemann, Kurt Linnemann